key: cord-0694182-cjcrtc7b
authors: Prada, Luísa; Santos, Catarina D.; Baião, Rita A.; Costa, João; Ferreira, Joaquim J.; Caldeira, Daniel
title: The Risk of SARS‐COV‐2 Infection and Covid‐19 Severity Associated with The Exposure to Non‐Steroidal Anti‐Inflammatory Drugs: Systematic Review and Meta‐Analysis
date: 2021-08-05
journal: J Clin Pharmacol
DOI: 10.1002/jcph.1949
sha: 148521ea15876452838fa543fc2089a0c6f0b68a
doc_id: 694182
cord_uid: cjcrtc7b

Non‐steroidal anti‐inflammatory drugs (NSAIDs) were thought to increase the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus entrance into cells. Hence, it was suggested in the media that NSAIDs could lead to a higher risk of infection and/or disease severity. To determine the existence or absence of this association, we aimed to systematically evaluate the risk of SARS‐CoV‐2 infection and mortality and the risk of severe coronavirus disease 2019 (COVID‐19) associated with previous exposure to NSAIDs. MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and EMBASE were searched in February 2021 for controlled studies. The results were calculated through random‐effect meta‐analyses and reported in terms of odds ratio (OR) with 95% confidence intervals (CI). Heterogeneity was assessed with I(2) test. Eleven studies were included, comprising a total of 683 715 patients. NSAID exposure did not increase the risk of having a positive test for SARS‐CoV‐2 infection (OR 0.97, 95% CI 0.85–1.11, I(2) = 24%, five studies). The exposure to NSAIDs did not increase the risk of severe/critical COVID‐19 disease (OR 0.92, 95% CI 0.80–1.05, I(2) = 0%, 5 studies) nor all‐cause mortality among patients with COVID‐19 (OR 0.86, 95% CI 0.75–0.99, I(2) = 14%, four studies). Our data did not suggest that exposure to NSAIDs increases the risk of having SARS‐CoV‐2 infection or increases the severity of COVID‐19 disease. Also, the fragility of the studies included precludes definite conclusions and highlights the need for further robust data. Systematic review registration number: CRD42020216806 This article is protected by copyright. All rights reserved

In December 2019, the first clusters of patients with pneumonia of unknown cause occurred in Wuhan, China. It was later confirmed that it was caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 This virus is responsible for coronavirus disease 2019 (COVID-19), a disease with a broad spectrum of clinical manifestations, of which fever is one of the main symptoms. [1] [2] [3] Non-steroidal anti-inflammatory drugs (NSAIDs) are broadly prescribed or sold over-the-counter to relieve fever and other inflammatory symptoms. 4 The main mechanism of action of NSAIDs is inhibition of the formation of prostaglandins (as well as prostacyclin and thromboxane) from arachidonic acid via inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2). 5, 6 However, in March 2020, French Health authorities warned against the use of ibuprofen for managing mild symptoms of COVID-19 due to the possibility of ibuprofen increasing the expression of the angiotensin-converting enzyme-2 (ACE-2) receptor, which is the target for cell penetration of the SARS-CoV-2 virus. [7] [8] [9] The World Health Organization (WHO) initially subscribed to this recommendation, but rapidly advised against it, since there was no clinical evidence to support it. 10 The change in recommendations highlighted the fragility of the available evidence for NSAID use and COVID-19 risk. This fragility could lead to doubts in clinical management. While a fever can be managed by other drugs such as acetaminophen, acute and chronic pain (osteoarticular or not) in some cases can benefit if managed with NSAIDs. The absence of solid evidence regarding the association of NSAIDs and COVID-19 disease, either of the risk of infection or prognostic impact, may preclude unequivocal drug management in these patients in the current pandemic context. This article is protected by copyright. All rights reserved. Therefore, we sought to systematically review all published controlled studies comparing the risks of NSAID and non-NSAID groups (irrespective of placebo use, standard of care, no treatment/exposure arms).

This systematic review followed the reporting principles of MOOSE 11 and PRISMA 12 . The protocol of this study was developed and registered in the International Prospective Register of Systematic Reviews (PROSPERO) with the following registration number CRD42020216806. The protocol was not published in any peer-reviewed journal. Conduct and reporting followed the PRISMA statement (see Supplemental Material 2) .

We considered eligible randomized controlled trials (RCTs), cohort/nested case-control studies, and case-control studies with information about the risk of infection or the risk of disease complications associated with NSAIDs compared with a control group.

Drug exposure was defined as exposure to any NSAID, including COX-2 inhibitors, at any dose (except patients treated with low-dose acid acetylsalicylic) and we accepted duration of treatment more than 30 days before SARS-CoV-2 infection documented or high clinical suspicion, to minimize protopathic bias. This cut-off point was defined clinically and based on the fact that these individuals would be using NSAIDs for reasons unrelated to symptoms.

Patients with a confirmed SARS-CoV-2 infection taking placebo, standard of care, or another analgesic drug, were considered eligible for control groups. Therefore, studies enrolling patients taking NSAIDs without a non-NSAIDs/placebo arm or patients taking NSAIDs less than 30 days before SARS-CoV-2 documented infection, were excluded.

The outcomes of interest were: 1) SARS-CoV-2 infection documented by: reverse transcription-polymerase chain reaction (RT-PCR); clinical and imaging features along with other laboratory testing (SARS-CoV-2 Ag-RDT, i.e.), or reported by authors as having high clinical suspicion of SARS-CoV-2 infection; 2) Critical disease outcome admitted in the analysis included hospital admission and progression to the intensive care unit (ICU) or admission directly to the ICU, which was defined according to the WHO's interim guidance; 13 3) All-cause Mortality. Furthermore, we aimed to undertake additional analyses to evaluate the association between NSAIDs and associated outcomes, such as the risk of hospitalization, risk of mechanical ventilation, or risk of ECMO. We also focused on NSAID safety, particularly, cardiovascular risk.

Case series, case reports, commentaries, and reviews were excluded.

The reviewers performed an electronic database search using MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and EMBASE to identify relevant studies (search strategy in Table S1 , Supplemental Material 1). We performed a sensitive search strategy for MEDLINE and EMBASE, which rely on MESH terms: "Anti-Inflammatory Agents", "Non-Steroidal". "Cyclooxygenase 2 Inhibitors", "'Nonsteroid anti-inflammatory agent" and "'Nonsteroid anti-inflammatory agent". In addition, a search was performed for additional articles by screening the references of potentially included studies for further review. The search was performed on 11th February 2021.

Three of the authors (CS, LP, RB) independently screened the search results for inclusion by assessing titles and abstracts. Discrepancies were resolved by consensus-based discussion or by a third reviewer (DC). Chance-corrected agreement between reviewers was assessed using the Cohen's Kappa statistic, a measure of the agreement between two ratters (reviewers) who each classified items into mutually exclusive categories. 14 The studies that were not excluded went to the full-text assessment phase. We excluded studies that provided no adjusted estimation and editorials or narrative reviews without original data. The motives for exclusion were recorded at this stage.

The risk of bias was independently evaluated by three authors (CS, LP, RB) using the Cochrane Risk of Bias Tool for RCTs and the ROBINS-I tool for observational studies. 15 We also assessed chance-corrected agreement between reviewers using the Cohen's Kappa statistic. 14 We also used the Downs and Black tool 16 to assess the methodological quality of the included studies by three reviewers (CS, LP, RB). Once again, all disagreements were resolved via third-party adjudication performed by a third author (DC).

We used RevMan (version 5.3) software for statistical analysis (The Nordic Cochrane Centre, The Cochrane Collaboration) and to derive forest plots showing the results of individual studies and pooled analysis, if feasible. A random-effects meta-analysis was performed by This article is protected by copyright. All rights reserved.

weighting by the inverse-variance method to estimate pooled odds ratio (OR) and 95% confidence intervals (95% CIs), irrespective of the statistical heterogeneity assessed through the I² statistic. We used the hazard ratio (HR) when OR was not available or not possible to calculate. Additional analysis according to the study design was performed. Publication bias assessment was performed through funnel plot examination and an Egger test ensuring a sufficient number of studies were included. A p-value ≤0.05 was considered significant.

The search returned 1372 records, resulting in 1180 records after removing duplicates.

Following abstract screening and evaluation of full-text eligibility, 76 articles were assessed for full-text screening, of these 11 were included for qualitative and quantitative syntheses.

( Figure 1 ; details of excluded studies at Table S2 , Supplemental Material 1). The Kappa for an inter-rater agreement was 0.53. The strength of agreement was moderate.

The main characteristics of the included studies 17-27 are depicted in Table 1 . The sample sizes ranged from 268 to 561 037 patients, with a total of 683 715 patients included in our review.

The majority of included studies were retrospective cohort studies (seven), one prospective, and three case-control studies ( Table 1) . No RCTs fulfilled our eligibility criteria. Two of the studies were conducted in patients with osteoarthritis and rheumatoid arthritis. 19, 27 Two studies were performed in Spain, two in the entire United Kingdom, two in Denmark, one in Scotland, one in Saudi Arabia, one in South Korea, one in France, and one in Italy. Almost all the included studies failed to report the type or the dose of NSAIDs used. In 10 of the studies included in the meta-analysis, the authors used matching methods to adjust the groups for confounding factors: five studies used Cox regression, four used logistic regression, two studies used the propensity score matching method and one study used Poisson regression.

The other study adjusted for confounding factors but did not report a matching method.

The risk of bias of the included studies assessed through ROBINS-I tool 15 was serious in three studies and moderate in the rest. All observational studies had a risk of bias due to confounding. The Kappa for inter-rater agreement was 0.54. The strength of agreement was considered moderate. See Supplemental Material 1, Table S3 , for more information regarding the quality assessment of the included studies.

The eleven included studies in this review scored from 12 to 14 (out of 28) on the Modified Downs and Black tool. 16 Table S4 (see Supplemental Material 1) summarizes the results of the risk of bias assessment using the Downs and Black assessment tool.

Five studies had information about COVID-19 infection (positive test) and NSAIDs and they were not associated with an increased risk of having a positive test for COVID-19 infection (OR 0.97, 95% CI 0.85-1.11; I 2 =24%; 5 studies) ( Figure 2 ). The analysis excluding population case-control studies 20, 24 showed similar results (OR 0.87, 95% CI 0.68-1.11; 3 studies) without statistical heterogeneity (I 2 =0%) ( Figure 3 ).

The risk of severe COVID-19 disease was evaluated in five studies. The risk of severe COVID-19 disease associated with NSAIDs was not significantly increased or decreased (OR 0.92, 95% CI 0.80-1.05; five studies) ( Figure 2 ). There was no significant heterogeneity in the analysis. When excluding the population case-control study 25 the estimate stood at OR 1.01 (95% CI 0.77-1.31; I 2 =6%; four studies) ( Figure 3 ).

The association between NSAIDs and mortality risk in patients with COVID-19 was evaluated in four studies. However, Wong et al. 27 , assessing primary care records (OpenSAFELY platform), identified and assessed two cohorts (people who had never used NSAIDs in the past three years from the general population and people with rheumatoid arthritis/osteoarthritis). Regarding all-cause mortality, NSAIDs were associated with neither an increase nor a reduction in the risk of this outcome: OR 0.86, 95% CI 0.75-0.99, I 2 = 14%, four studies ( Figure 2 ). We performed a subsequent exploratory subgroup analysis for all types of NSAIDs, where we did not apply the time of exposure eligibility criterion. However, only two authors (Drake et al. 28 and Wong et al. 27 ) had data available for ibuprofen. This subgroup analysis did not significantly increase or reduce the risk of COVID-19 deaths (OR 0.98, 95% CI 0.78-1.22; 2 studies) (See Figure S1 , Supplemental Material 1).

We performed an additional analysis where we included studies where we did not apply the time of exposure eligibility criterion. Thereby, we observed that the risk of severe COVID-19 infection was not significantly increased (OR 1.05, 95% CI 0.88-1.25, seven studies [Drake et al. 28 and Jeong et al. 29 were included]) with a significant heterogeneity (I 2 = 54%). Regarding mortality, NSAIDs were also not associated with neither an increase nor a reduction in the risk of this outcome (OR 0.85, 95% CI 0.74-0.96, I 2 = 42%; Bruce et al. 30 , Drake et al. 28 and Imam et al. 31 were included) ( Figure S2 , Supplemental Material 1).

About the risk of mechanical ventilation in patients with COVID-19, only two authors had data available. This outcome was not significantly increased or decreased (OR 0.97, 95% CI 0.82-1.16; 2 studies). There was no significant heterogeneity in the analysis ( Figure S3 , Supplemental Content). Data were not available for other associated outcomes.

We were unable to perform an analysis of cardiovascular safety outcomes since data were not available for these outcomes.

Additionally, the Egger test was not statistically significant for the risk of having COVID-19 infection (p-value = 0.17), risk of mortality among those COVID-19 symptomatic (p-value = 0.50), and risk of severe disease among those with COVID-19 (p-value = 0.02). The funnel plots are depicted in Figure S4 , Supplemental Material 1.

Our main findings were: 1) NSAIDs were not associated with an increased risk of being infected with SARS-CoV-2; 2) Among patients with COVID-19, the previous exposure to NSAIDs did not increase the risk of severe disease or mortality.

Concerns about the use of NSAIDs in patients with COVID-19 have been raised based on unpublished data. Theoretically, it was claimed that drugs such as angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), and ibuprofen could upregulate the ACE-2, which might mediate the entrance of SARS-CoV-2 in epithelial cells, increasing the chance of having COVID-19 and worsening a patient's prognosis. Also, NSAIDs might delay the diagnosis of COVID-19 by masking inflammation and fever. Such claims led to alarmism in the scientific and non-scientific community, since NSAIDs are highly used in various conditions, and they are broadly prescribed or sold over-the-counter.

Since then, several studies have attempted to understand the effects of different drug classes in ACE-2 expression and their effects on the stability of ACE-2 and viral receptor-binding protein complexes. A recent review shows that when NSAIDs are taken continuously, with consequent inhibition of COX, the glomerular filtration rate and renal perfusion are reduced.

This increases angiotensin II levels and may initiate a compensatory mechanism with subsequent upregulation of ACE-2 expression to counteract angiotensin II. This could make larger amounts of ACE-2 available for SARS-CoV-2 entry into the cell. 32 Contrarily, a study in computational modeling found that some NSAIDs, such as ibuprofen, aspirin, and acetaminophen, can alter the stability between the viral receptor-binding protein and ACE-2. 33 Another study, in asthmatic patients, found that daily aspirin in an anti-inflammatory dose was not associated with increased transcription of ACE-2 or angiotensin-derived peptides. 34 These findings do not directly point to a beneficial effect of NSAIDs in SARS-CoV-2 infection, but they do imply that there is still much to learn about the interaction between the virus and its entry-gate enzyme.

In some non-COVID-19 preclinical studies, NSAIDs were associated with suppression of IL-6 production and, also, suppression of prostaglandin E2, which upregulates the production of IL-6 and IL-8. 35 These pro-inflammatory mediators are also associated with more severe COVID-19, 36, 37 since hyperinflammatory responses are the basis of the pathology of severe cases of this disease, such as ARDS. 38 Additionally, the growing body of evidence points to the importance of anti-inflammatory drugs, such as corticosteroids or drugs that inhibit the production of IL-6, in severe cases. However, it is hypothesized that, in early phases of COVID-19, this concomitant immunosuppression could promote SARS-CoV-2 replication. 32 Other studies observed that different NSAID types could have different capabilities to suppress enzymatic activities of COX-1 and COX-2, 39, 40 which implies a variety of effects that influence the study results. Unfortunately, data were scarce, and we were unable to categorize NSAIDs. Therefore, more research is needed to evaluate if NSAID type can increase or decrease the risk of poorer outcomes in COVID-19 patients.

Regarding clinical studies, several authors observed that NSAID use does not appear to increase the risk of poorer outcomes in COVID-19 patients. Drake et al. 28 included a large number of patients admitted to hospital with COVID-19 (n= 72179; the authors used data from the ISARIC Clinical Characterization Protocol UK cohort), across 255 healthcare facilities in England, Scotland, and Wales. This study aimed to analyze the association between NSAIDs and severe COVID-19 outcomes, including mortality, critical care admission, need for invasive ventilation, need for oxygen, and acute kidney injury. Drake et al. 28 observed that NSAID use was not associated with higher mortality or increased severity of COVID-19. However, data on dosages and treatment duration were not available.

Therefore, the authors were unable to assess whether there is a potentially harmful effect or not associated with drug dosages or treatment duration.

Although there is still no pharmacodynamically clear answer for this question, the data from our systematic review did not show an association between NSAIDs and an increased risk of infection or disease complications. The relevance of these data is of the utmost importance for patients who are treated chronically with these drugs as safety is being assured. In the symptomatic relief of fever, other options exist, such as acetaminophen, but our data show that NSAIDs can be added to the therapeutic options available.

In this context, the judgment of media reports and observational studies is always difficult as data are frequently prone to bias. For example, social media reported four cases of younger patients with COVID-19 whose condition worsened after taking ibuprofen for symptomatic relief. 41 This report and other studies might be at high risk of residual confounding and selective reporting bias which precludes definite conclusions. Another example relies on a systematic review of observational studies that reported a positive association between NSAIDs and pneumonia complications. 42 To decrease the risk of bias we were conservative in our analysis since we extracted data reporting only adjusted measures and respecting the directionality and significance of the results.

Despite the concerns regarding NSAIDs, the anti-inflammatory features of corticosteroids have been demonstrated to decrease mortality in patients requiring oxygen or mechanical ventilation. 43 The inflammatory pathways in this infection still require further research so that we can understand the exact mechanisms by which these drugs might influence health outcomes.

We were unable to assess NSAID safety since there were no available data. However, we have to be aware that NSAIDs are also associated with gastrointestinal complications (like peptic ulcer disease and gastrointestinal bleeding) and the risk of cardiovascular adverse events. 44 Therefore, the choice of drug to treat anti-inflammatory symptoms associated with COVID-19 should be based on a benefit-risk assessment for known side effects and NSAIDs should be used at the lowest effective dose for the shortest possible period.

Our review has limitations inherent to the included studies themselves. Due to our inclusion criteria, in our search, we only retrieved observational studies with their inherent bias. Also, all the observational studies included had a high risk of bias, leading to low confidence in the results. By default, our data were subjected to a high protopathic and confounding bias. To avoid that, we restricted our search to the use of NSAIDs for at least 30 days prior to Most of the studies included were unable to provide data on NSAID type, dosage, and total treatment duration. Therefore, we could not assess whether there was a potentially harmful effect of NSAIDs masked by variables. Future studies should be aware of details regarding the use of NSAIDs, including the effects of continuation or discontinuation after hospital admission, type, dosage, and treatment duration.

When we assessed the outcomes of interest, low statistical heterogeneity was observed, which is a good indicator of the robustness of the result, despite the baseline heterogeneity of the population. Also, when studies with less robust designs were excluded, the estimates kept their neutrality in terms of significance without statistical heterogeneity.

Our study analyzed the best available evidence and it is relevant to inform all stakeholders about the safety of using NSAIDs and the risk of COVID-19 disease. 

Not applicable.

As this is a review article, ethical approval was not necessary.

All data generated or analyzed during this study are included in this published article (and its supplementary information files).

Abu Esba LC, Alqahtani RA, Thomas A, Shamas N, Alswaidan L, Mardawi G. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet

The outbreak of COVID-19: an overview

Epidemiology and clinical features of COVID-19: A review of current literature

Non-steroidal antiinflammatory drugs for the common cold

Variability in the response to non-steroidal antiinflammatory drugs: Mechanisms and perspectives. Basic and Clinical Pharmacology and Toxicology

The Coxibs, selective inhibitors of cyclooxygenase-2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine

A crucial role of angiotensin converting enzyme 2

Who. COVID-19 and treatment with NSAIDs and corticosteroids: Should we be limiting their use in the clinical setting?

Meta-analysis of observational studies in epidemiology: A proposal for reporting

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

Clinical management of severe acute respiratory infection (SARI) when

COVID-19 disease is suspected. Interim guidance. Interim guidance

The measurement of observer agreement for categorical data

ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions

The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions